Concord Biotech Limited is a leading biotechnology company based in India. The company specializes in the development, manufacturing, and commercialization of active pharmaceutical ingredients (APIs), advanced intermediates, and fermentation-based products for various therapeutic areas including oncology, anti-fungals, immunosuppressants, antibiotics, and others.

Concord Biotech has an extensive product portfolio that includes several high-quality APIs such as Tacrolimus, Sirolimus, Everolimus, Pimecrolimus, Mycophenolate Mofetil (MMF), Micafungin Sodium along with other innovative fermentation-based products.

The company's state-of-the-art research and development facilities are dedicated to developing innovative technologies and processes for cost-effective production of complex molecules through microbial fermentations. Concord Biotech has also established itself as a preferred partner for custom synthesis solutions catering to the specific requirements of global pharmaceutical companies. One key aspect that sets Concord Biotech apart from its competitors is its strong focus on sustainability and environmental responsibility. The company adheres to stringent quality standards and maintains a commitment to eco-friendly practices throughout its operations. In terms of collaborations and partnerships, Concord Biotech has forged alliances with international organizations for technology transfer initiatives while also engaging in strategic partnerships with global pharma majors for co-development projects. Overall, Concord Biotech Limited's dedication to innovation, sustainable practices, diverse product range,and collaborative approach positions it as a prominent player in the biotechnology industry.